Fibrin binding domain polypeptides and uses and methods of producing same
AssigneeBio-Technology General Corp.
InventorsTikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
Life of this patent
Estimating the term…
Loading patent…
AssigneeBio-Technology General Corp.
InventorsTikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
Estimating the term…
This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus-or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and which are capable of binding to fibrin.
An imaging agent which comprises a polypeptide labeled with an imageable marker, wherein the polypeptide has a molecular weight between about 12 and about 20 kD and an amino acid sequence substantially the same as an amino acid sequence present in the fibrin binding domain of naturally-occurring fibronectin, and having the amino acid sequence gln-ala-gln-gln or met-gln-ala-gln-gln at the N-terminus of the polypeptide and wherein the imaging agent is capable of binding to fibrin.
A purified polypeptide substantially free of other substances of human origin, wherein the polypeptide has a molecular weight between about 12 and about 20 kD and an amino acid sequence substantially the same as an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin, and having the amino acid sequence gln-ala-gln-gln or met-gln-ala-gln-gln at the N-terminus of the polypeptide, and is capable of binding to fibrin.
Dependencies are inferred from the claim text.